Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bloomberg Natural Gas ETF vs Merck & Co., Inc. — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.7, while Merck & Co., Inc. trades at $133.12 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BOIL | MRK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $87.24 | $131.84 |
52-Week Low | $18.74 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOIL trades at $20.73, showing minimal daily movement with a 0.1% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators remain neutral. The stock faces resistance at $21 with support at $20. Recent corporate actions include a 1:2 stock split scheduled for May 28, 2026. Natural gas market volatility and weather-dependent demand continue to influence price movements.
The outlook remains cautious given bearish technical signals and natural gas market uncertainty. Investment opportunities exist for tactical traders during volatility spikes, but risks include weather-dependent demand fluctuations and production increases. The stock split may improve liquidity but doesn't alter fundamental valuation. Investors should monitor EIA storage reports and weather forecasts as key catalysts.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
